Total pharma industry venture financing deals in February 2019 worth $1.7bn were announced globally, according to GlobalData’s deals database.
Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 14.2% over the previous month and a drop of 5.2% when compared with the last 12-month average, which stood at $1.79bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $1.04bn. At the country level, the US topped the list in terms of deal value at $1.04bn.
In terms of volumes, North America emerged as the top region for pharma industry venture financing deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of venture financing deals activity in February 2019 was the US with 46 deals, followed by China with six and Switzerland with six.
In 2019, as of the end of February 2019, pharma venture financing deals worth $3.68bn were announced globally, marking an increase of 0.6% year on year.
Pharma industry venture financing deals in February 2019: Top deals
The top five pharma industry venture financing deals accounted for 44.8% of the overall value during February 2019.
The combined value of the top five pharma industry venture financing deals stood at $762.04m, against the overall value of $1.7bn recorded for the month. The top announced pharma industry venture financing deal tracked by GlobalData in February 2019 was Alexandria Venture Investments, ARCH Venture Partners, Casdin Capital, Foresite Capital Management, GV Management Co and Third Rock Ventures’ $191m venture financing of Maze Therapeutics.
In second place was the $179.86m venture financing of Arvelle Therapeutics by BRV Capital Management, Andera Partners, H.I.G. BioHealth Partners, Life Sciences Partners and NovaQuest Capital Management and in third place was Biotechnology Value Fund, Curative Ventures, Driehaus Capital Management, EcoR1 Capital, Eventide Asset Management, Foresite Capital Management, Nextech Invest, Orbimed Advisors, RA Capital Management, The Column Group, Tichenor Ventures, Topspin Fund and Vida Ventures’ $150m venture financing of Peloton Therapeutics.
The $125.67m venture financing of Burning Rock Biotech by CMB International Capital Management (Shenzhen), GIC, Lilly Asia ventures, LYFE Capital and Sequoia Capital China and Frazier Healthcare Partners, Lilly Asia ventures, New Leaf Venture Partners, Orbimed Advisors, Versant Venture Management and Vivo Capital’s venture financing of Passage Bio for $115.5m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.